No definition available.

Name:	isis_CollaborativeArrangementAndLicensingAgreementAbstract
Namespace Prefix:	isis_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Cumulative amount of payments received under the collaborative arrangement as of the end of the reporting period.

+ References

No definition available.

+ Details

Name:	isis_CumulativePaymentsReceived
Namespace Prefix:	isis_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Represents the maximum amount of payments receivable per drug under the agreement.

+ References

No definition available.

+ Details

Name:	isis_MaximumAmountOfPaymentReceivablePerDrug
Namespace Prefix:	isis_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Represents the period from the inception of the collaboration during which a change of control could result in the entity being required to refund the upfront payment received.

+ References

No definition available.

+ Details

Name:	isis_PeriodFromInceptionOfCollaborationDuringWhichChangeOfControlMayResultInRefundOfUpfrontPayment
Namespace Prefix:	isis_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Represents the next prospective milestone payment to be earned.

+ References

No definition available.

+ Details

Name:	isis_ProspectiveMilestonePayment
Namespace Prefix:	isis_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-Section 50

-Paragraph 18

-URI http://asc.fasb.org/extlink&oid=6927468&loc=d3e6351-108592

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 20

-URI http://asc.fasb.org/extlink&oid=35750535&loc=d3e13531-108611

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-Section 50

-Paragraph 20

-URI http://asc.fasb.org/extlink&oid=6927468&loc=d3e6404-108592

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 21

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=35750535&loc=d3e13537-108611

+ Details

Name:	us-gaap_ConcentrationRiskPercentage1
Namespace Prefix:	us-gaap_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount of deferred revenue as of balance sheet date. Deferred revenue represents collections of cash or other assets related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 605

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 13.A.4(a).Q1 Response)

-URI http://asc.fasb.org/extlink&oid=27012821&loc=d3e214044-122780

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 13

-Section A

+ Details

Name:	us-gaap_DeferredRevenue
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Amount of deferred revenue recognized for transactions arising during the current reporting period. Deferred revenue is a liability as of the balance sheet date related to a revenue producing activity for which revenue has not yet been recognized. Generally, an Entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 605

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 13.A.4(a).Q1)

-URI http://asc.fasb.org/extlink&oid=27012821&loc=d3e214044-122780

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 13

-Section A

+ Details

Name:	us-gaap_DeferredRevenueAdditions
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

The amount of consideration recognized during the period for the milestone or milestones.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 605

-SubTopic 28

-Section 50

-Paragraph 2

-Subparagraph (e)

-URI http://asc.fasb.org/extlink&oid=19771982&loc=SL6892177-166501

+ Details

Name:	us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.1)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 1

-Article 5

+ Details

Name:	us-gaap_Revenues
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Details

Name:	us-gaap_CounterpartyNameAxis=isis_BiogenIdecMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=isis_CollaborativeArrangementsAndLicensingAgreementsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueGoodsNetMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=isis_CollaborativeArrangementSeptember2013Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ProductOrServiceAxis=isis_StrategicNeurologyMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RangeAxis=us-gaap_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	isis_OtherProductsAndServicesAxis=isis_AntisenseDrugForNeurologicalDiseaseMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	isis_AchievementOfMilestoneAxis=isis_LicenseAndSubstantiveMilestonesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	isis_AchievementOfMilestoneAxis=isis_ResearchAndDevelopmentMilestonesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	isis_AchievementOfMilestoneAxis=isis_RegulatoryMilestonesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	isis_OtherProductsAndServicesAxis=isis_OtherDrugsExcludingAntisenseDrugForNeurologicalDiseaseMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	isis_AchievementOfMilestoneAxis=isis_PreSpecifiedEventsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Collaborative Arrangements and Licensing Agreements, Traditional Pharmaceutical Alliances and Licensing - Biogen Idec (Strategic Neurology) (Details) - USD ($) $ in Thousands	1 Months Ended		3 Months Ended		6 Months Ended
	Apr. 30, 2015	Sep. 30, 2013	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Collaborative Arrangement and Licensing Agreement [Abstract]
Revenue earned			$ 120,428	$ 57,076	$ 183,012	$ 85,237
Biogen Idec [Member] \| Collaborations and Licensing Agreements [Member]
Collaborative Arrangement and Licensing Agreement [Abstract]
Revenue earned			17,800	$ 34,500	57,000	$ 44,700
Deferred revenue			$ 105,000		$ 105,000
Biogen Idec [Member] \| Collaborations and Licensing Agreements [Member] \| Revenue [Member] \| Strategic Partner [Member]
Collaborative Arrangement and Licensing Agreement [Abstract]
Concentration percentage			15.00%		31.00%
Biogen Idec [Member] \| Agreement Entered into in September 2013 [Member] \| Strategic Neurology [Member]
Collaborative Arrangement and Licensing Agreement [Abstract]
Upfront fee recorded as deferred revenue		$ 100,000
Period during which a change in control could result in requirement to refund upfront payment					6 years
Cumulative payments received			$ 135,000		$ 135,000
Milestone payment earned	$ 10,000
Biogen Idec [Member] \| Agreement Entered into in September 2013 [Member] \| Strategic Neurology [Member] \| Maximum [Member]
Collaborative Arrangement and Licensing Agreement [Abstract]
Next prospective milestone			10,000		10,000
Biogen Idec [Member] \| Agreement Entered into in September 2013 [Member] \| Strategic Neurology [Member] \| Antisense Drug for Neurological Disease [Member] \| License Fee and Substantive Milestones [Member]
Collaborative Arrangement and Licensing Agreement [Abstract]
Maximum amount of payment receivable per drug			260,000		260,000
Biogen Idec [Member] \| Agreement Entered into in September 2013 [Member] \| Strategic Neurology [Member] \| Antisense Drug for Neurological Disease [Member] \| Research and Development Milestones [Member]
Collaborative Arrangement and Licensing Agreement [Abstract]
Maximum amount of payment receivable per drug			60,000		60,000
Biogen Idec [Member] \| Agreement Entered into in September 2013 [Member] \| Strategic Neurology [Member] \| Antisense Drug for Neurological Disease [Member] \| Regulatory Milestones [Member]
Collaborative Arrangement and Licensing Agreement [Abstract]
Maximum amount of payment receivable per drug			130,000		130,000
Biogen Idec [Member] \| Agreement Entered into in September 2013 [Member] \| Strategic Neurology [Member] \| Other Modalities [Member] \| Pre-specified Events [Member]
Collaborative Arrangement and Licensing Agreement [Abstract]
Maximum amount of payment receivable per drug			90,000		90,000
Biogen Idec [Member] \| Agreement Entered into in September 2013 [Member] \| Strategic Neurology [Member] \| Other Modalities [Member] \| Research and Development Milestones [Member]
Collaborative Arrangement and Licensing Agreement [Abstract]
Maximum amount of payment receivable per drug			35,000		35,000
Biogen Idec [Member] \| Agreement Entered into in September 2013 [Member] \| Strategic Neurology [Member] \| Other Modalities [Member] \| Regulatory Milestones [Member]
Collaborative Arrangement and Licensing Agreement [Abstract]
Maximum amount of payment receivable per drug			$ 55,000		$ 55,000